Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative

By sjmartinez • November 15, 2024

Wohl DA, Adam SJ, Gibbs KW, Moskowitz AL, Ortel TL, Singh U, Jilg N, Evering TH, Fischer WA 2nd, Taiwo BO, Daar ES, Lindsell CJ, Naggie S, Rothman RL, Dunsmore SE, McAdams MP, Vail J, Jayaweera D. Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative. J Clin Transl Sci. 2024 Oct 15;8(1):e156. doi: 10.1017/cts.2024.561. PMID: 39540112; PMCID: PMC11557280.

Tags: antiviral treatment trials, community engagement, covid-19, Infectious Diseases, outbreaks, outreach, Pandemic, Publications

Related Posts

Integration of HIV pre-exposure prophylaxis (PrEP) services for pregnant and breastfeeding women in eight primary care clinics: results of an implementation science study

Nelson A, Bheemraj K, Dean SS, de Voux A, Hlatshwayo L, Mvududu R, Berkowitz N, Neumuller C, Jacobs S, Fourie S, Coates T, Gail-Bekker L,[...]

How I Do It: Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes

Donovan FM, Thompson GR 3rd, Blair JE, Johnson RH, Malo J, Albasha W, Worrell SG, Beamer SE, Yaddanapudi K, Galgiani JN, Ampel NM. How I[...]

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]